Logo
x

Search

Subscribe Now

Modalis Therapeutics

Modalis Therapeutics’ MDL-101 Gains the US FDA’s Orphan Drug Designation to Treat Congenital Muscular Dystrophy Type 1A (LAMA2-CMD)

Modalis Therapeutics’ MDL-101 Gains the US FDA’s Orphan Drug Designation to Treat Congenital Muscular Dystrophy Type 1A (LAMA2-CMD...

  • October 28, 2024
Modalis Therapeutics Unveils Epigenome Editing Therapy MDL-101 for Treatment of LAMA2-Deficient CMD

Modalis Therapeutics Unveils Epigenome Editing Therapy MDL-101 for Treatment of LAMA2-Deficient CMD

  • May 7, 2024
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.